Posted by Michael Wonder on 08 Jan 2024
ICER publishes final evidence report on treatment for pulmonary arterial hypertension
8 January 2024 - Independent appraisal committee voted that sotatercept demonstrated a net health benefit when compared to background therapy; sotatercept would achieve common thresholds for cost-effectiveness if priced between $17,900 - $35,400/year.
The ICER today released a final evidence report assessing the comparative clinical effectiveness and value of sotatercept (Merck/MSD) for pulmonary arterial hypertension.
